Friday 23 June 2023, Amsterdam
The global viral vector and plasmid DNA manufacturing market is projected to reach USD 12.8 billion by 2028 from USD 5.5 billion in 2023, at a CAGR of 18.2% during the forecast period of 2023 to 2028.
The growth of this market can be attributed to the availability of funding for the development of gene therapy. Gene therapy is a rapidly growing field, and funding is needed for research and development, clinical trials, and manufacturing. For instance, in December 2022, SonoThera, a biotechnology company announced completion of its USD 60.75 million Series A financing round. The financing will support the continued development of SonoThera’s ultrasound-guided, nonviral, gene therapy platform and treatments, designed to provide patients with genetic medicines.
In 2022, vector amplification, editing and expansion segment accounted for the largest share by upstream manufacturing process in the global viral vector and plasmid DNA manufacturing market. Vector amplification, editing, and expansion are critical steps in viral vector and plasmid DNA manufacturing as they directly impact the quantity, quality, and functionality of the vectors. The pharmaceutical and biopharmaceutical industry is witnessing significant advancements, particularly in the development of novel therapeutics and vaccines. Viral vectors and plasmid DNA are crucial tools for delivering therapeutic genes or vaccine antigens. The demand for vector amplification, editing, and expansion is driven by the need to produce a diverse range of viral vectors and plasmid DNA for various therapeutic and vaccine candidates.
This report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.
ASDReports.com contact: S. Koomen
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216
back to News
